Adamas Pharma
(ADMS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -51,802 | 10,223 | 50,921 | 17,736 |
| Depreciation Amortization | 1,310 | -1,206 | 66 | 41 |
| Accounts receivable | -760 | -395 | 761 | -516 |
| Accounts payable and accrued liabilities | -788 | 1,521 | -1,157 | 1,799 |
| Other Working Capital | -6,674 | 10,479 | -29,404 | 31,455 |
| Other Operating Activity | 11,504 | 7,171 | 5,614 | 1,446 |
| Operating Cash Flow | $-47,210 | $27,793 | $26,801 | $51,961 |
| Cash Flows From Investing Activities | ||||
| Change In Deposits | 9,457 | -96,095 | N/A | N/A |
| PPE Investments | -1,399 | -1,285 | -167 | -24 |
| Investing Cash Flow | $8,058 | $-97,380 | $-167 | $-24 |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | 10,403 | 45,629 | 21 | 3,955 |
| Common Stock Repurchased | N/A | -370 | 0 | N/A |
| Other Financing Activity | 407 | 162 | -4,000 | 3,948 |
| Financing Cash Flow | $10,810 | $45,421 | $-3,979 | $7,903 |
| Beginning Cash Position | 61,446 | 85,612 | 62,957 | 3,117 |
| End Cash Position | 33,104 | 61,446 | 85,612 | 62,957 |
| Net Cash Flow | $-28,342 | $-24,166 | $22,655 | $59,840 |
| Free Cash Flow | ||||
| Operating Cash Flow | -47,210 | 27,793 | 26,801 | 51,961 |
| Capital Expenditure | -1,399 | -1,285 | -167 | -24 |
| Free Cash Flow | -48,609 | 26,508 | 26,634 | 51,937 |